Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)

Type 2 Diabetes Clinical Trial

— Malbec  

Official title:

A 24 Weeks, Randomized, 2 Arms, Controlled, Multi-centre, National, Open-labeled, Parallel Study in Insulin naïve Patients With Type 2 Diabetes to Compare a Lantus Titration Algorithm vs. Physician's Standard Practice

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00627471
• Other study ID #: LANTU_L_02936
• Status: Terminated
• Phase: Phase 4
• First received: February 22, 2008
• Last updated: June 1, 2010
• Start date: January 2008

Study information

• Verified date: June 2010
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Argentina: Human Research Bioethics Committee
• Study type: Interventional

Clinical Trial Summary

To compare in terms of HbA1c insulin naive patients with Type 2 Diabetes starting with insulin glargine on an algorithm with insulin naive patients starting with insulin glargine on the physician's standard practice.

To compare in terms of FBG insulin naïve patients starting with insulin glargine on an algorithm with insulin naïve patients starting with insulin glargine on the physician's standard practice.

To compare the percentage of patients achieving HbA1c< 7% in each treatment group.

To compare hypoglycaemic events (minor, severe and nocturnal) between groups.

To compare average insulin dose between groups.

To compare PRO (patients' reported outcomes) between groups.

To compare mean changes in body weight between treatment groups.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 74 Years

Eligibility

Inclusion Criteria:

• Patients with type 2 diabetes.

• Patients in treatment with OADs (one or more) for at least 1 year who failed metabolic control (HbA1c > 8% and < 11%).

• FBG > 130 mg/dl and < 240 mg/dl.

• BMI < 40 kg/m2 and >25 kg/m2.

• Ability and willingness to follow a tight anti-diabetic therapy and to perform SMBG controls.

Exclusion Criteria:

• C peptide < 0.30 nmol/l.

• Unexplained weight loss of more than 10% of body weight in the last 6 months.

• Pregnant women or women with the intention of becoming pregnant.

• Women with childbearing potential who will not use contraceptive protection.

• Breastfeeding women.

• Patients using or that have used rapid or ultra-rapid acting insulins; except for those patients that have used rapid or ultra-rapid insulins during intercurrences such as AMI, severe infection or surgery.

• Renal impairment defined as serum creatinine >1.4 mg/dl in women and >1.5 mg/dl in men.

• Hepatic impairment defined as GPT or GOT above 2x the normal threshold.

• Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (non selective beta blockers and systemic corticosteroids).

• History of drug or alcoholic abuse.

• Diabetic retinopathy with surgical treatment in the 3 months prior to study entry or which may require surgical treatment within 6 months of study entry.

• Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological, endocrine, hematological, oncologic or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, at the discretion of the investigator.

• Evidence of an uncooperative attitude, including poor compliance to any anti- diabetic treatment.

• Known hypersensitivity to insulin glargine.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Drug:
• Insulin Glargine
For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
• Insulin Glargine
In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician. For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.

Locations

Country	Name	City	State
Argentina	Sanofi-aventis administrative office Argentina	Buenos Aires

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean difference in HbA1c (efficacy)		6 months	No
Secondary	Minor, severe and nocturnal Hypoglycaemic events (safety)		from the begining of the treatment up to 5 days after the end of the study	Yes